Laurus Labs Ltd.

“Laurus Labs is a technically competent, founder-led manufacturer executing a credible CDMO pivot from a structurally weakening ARV API base, but the combination of ~3.3x Net Debt/EBITDA, sub-cost-of-capital ROCE, an unproven CDMO ramp, and a 20-30% probability PEPFAR termination risk that threatens ~40-45% of revenue makes this a high-risk business — and at 74.6x trailing and 49.2x forward P/E near its 52-week high, the stock prices in the best-case outcome with zero margin of safety, implying ~32% downside on probability-weighted intrinsic value.”